Diagnosis of intraurothelial neoplasia interobserver variation and the value of individual histopathologic attributes

Analytical and Quantitative Cytology and Histology

Volumn 33, Issue 2, 2011, Pages 75-81

  Isfoss, Björn L ^a   Majak, Bernard ^a   Busch, Christer ^b   Braathen, Geir J ^a,c  

^a Telemark Hospital   (Norway)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bladder cancer; Carcinoma in situ; Diagnosis; Interobserver variation; Pathology

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER TUMOR; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE;

CARCINOMA IN SITU; HUMANS; OBSERVER VARIATION; RECURRENCE; UROLOGIC NEOPLASMS;

EID: 79955653866     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R: The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-1330.
3. Melicow MM: Histological study of vesical urothelium intervening between gross neoplasms in total cystectomy. J Urol 1952;68:261-279.
4. Melamed MR, Voutsa NG, Grabstald H: Natural history and clinical behavior of in situ carcinoma of the human urinary bladder. Cancer 1964;17:1533-1545.
5. Cheng L, Cheville JC, Neumann RM, Bostwick DG: Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999;23:443-447.
6. Jacobsen F, Møller-Nielsen C, Mommsen S: Flat intra-epithelial carcinoma in situ of the urinary bladder. Scand J Urol Nephrol 1985;19:253-255.
7. Althausen AF, Prout GR Jr, Daly JJ: Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976;116:575-580.
8. Tannenbaum M, Madden JF: Diagnostic Atlas of Genitourinary Pathology. New York, Churchill Livingstone, 2006.
9. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (editors): WHO Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, IARC Press, 2004.
10. Epstein JI, Amin MB, Reuter VR, Mostofi FK; Bladder Consensus Conference Committee: The World Health Organization/International Society of Urological Pathology Consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22:1435-1448.
11. Brawn PN: The origin of invasive carcinoma of the bladder. Cancer 1982;50:515-519.
12. Kaye KW, Lange PH: Mode of presentation of invasive bladder cancer: Reassessment of the problem. J Urol 1982;128:31-33.
13. Koss LG, Tiamson EM, Robbins MA: Mapping cancerous and precancerous bladder changes: A study of the urothelium in ten surgically removed bladders. JAMA 1974;227:281-286.
14. Koss LG: Mapping of the urinary bladder: Its impact on the concepts of bladder cancer. Hum Pathol 1979;10:533-548.
15. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M; Hexvix PCB301/01 Study Group: Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171:135-138.
16. Draga RO, Grimbergen MC, Kok ET, Jonges TN, Bosch JL: Predictors of false positives in 5-aminolevulinic acidinduced photodynamic diagnosis of bladder carcinoma: Identification of patient groups that may benefit most from highly specific optical diagnostics. Urology 2009;74:851-857.
17. Jung I, Messing EM, Fradet Y: Diagnosis of bladder cancer. In Bladder Cancer: Current Diagnosis and Treatment. Edited by MJ Droller. Totowa, NJ, Humana Press, 2001, pp 57-83.
18. Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nelson RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS, Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB, O'Kane DJ: A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002;167: 2001-2006.
19. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, Zadra J, Burzon D, Osher G, Bridge JA, Anderson S, Johansson SL, Lieber M, Soloway M, Flom K: Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168:1950-1954.
20. Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS, Procop GW, Jones JS, Ulchaker J, Zippe CD, Tubbs RR: Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003;169:2101-2105.
21. Gudjonsson S, Isfoss BL, Hansson K, Domanski AM, Warenholt J, Soller W, Lundberg LM, Liedberg F, Grabe M, Månsson W: The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 2008;54:402-408.
22. Isfoss BL, Majak B, Busch C, Braathen GJ: Simplification of grading papillary urothelial neoplasia using a reduced set of diagnostic features. Anal Quant Cytol Histol 2011;33:68-74.
23. Montironi R, Lopez-Beltran A: The 2004 WHO classification of bladder tumors: A summary and commentary. Int J Surg Pathol 2005;13:143-153.
24. McKenney JK, Gomez JA, Desai S, Lee MW, Amin MB: Morphologic expressions of urothelial carcinoma in situ: A detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol 2001;25:356-362.
25. Cheng L, Lopez-Beltran A, MacLennan GT, Montironi R, Bostwick DG: Neoplasms of the bladder. In Urologic Surgical Pathology. Edited by DG Bostwick, L Cheng. Philadelphia, Mosby Elsevier, 2008, pp 263-272.
26. Koss LG, Melamed MR (editors): Tumors of the urinary tract in urine and brushings. In Koss' Diagnostic Cytology. 5th Edition. Philadelphia, Lippincott Williams & Wilkins, 2006, pp 777-846.
27. Epstein JI, Amin MB, Reuter VE (editors): Flat epithelial lesions. In Bladder Biopsy Interpretation. Philadelphia, Lippincott Williams & Wilkins, 2004, pp 11-34.
28. Magi-Calluzzi C, Zhou M, Epstein JI: Neoplasms of the urinary bladder. In Genitourinary Pathology. New York, Churchill Livingstone, 2007, pp 109-153.
29. Mufti GR, Singh M: Value of random mucosal biopsies in the management of superficial bladder cancer. Eur Urol 1992;22: 288-293.
30. Flamm J, Dona S: The significance of bladder quadrant biopsies in patients with primary superficial bladder carcinoma. Eur Urol 1989;16:81-85.
31. Mostofi FK, Sobin LH, Torlini H: Histological typing of urinary bladder tumours. In International Classification of Tumours, No. 10. Geneva, World Health Organization, 1973, pp 18-19.
32. Mostofi FK, Davis CJ, Sesterhenn IA: World Health Organization International Histological Classification of Tumours. Edited by FK Mostofi, CJ Davis. New York, Springer, 1999, p 12.
33. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Schellhammer PF, Seigne JD, Skinner EC, Wolf JS (editors): The management of bladder cancer: Diagnosis and treatment recommendations. In Guidelines for the Management of Nonmuscle Invasive Bladder Cancer: 2007 Update. American Urological Association, 1997. Available at: www.auanet.org.
34. Giella JG, Ring K, Olsson CA, Karp FS, Benson MC: The predictive value of flow cytometry and urinary cytology in the follow up of patients with transitional cell carcinoma of the bladder. J Urol 1992;148:293-296.
35. Smith G, Elton RA, Beynon LL, Newsham JE, Chisholm GD, Hargreave TB: Prognostic significance of biopsy results of normal-looking mucosa in cases of superficial bladder cancer. Br J Urol 1983;55:665-669.
36. Norming U, Tribukait B, Nyman CR, Nilsson B, Wang N: Prognostic significance of mucosal aneuploidy in stage Ta/T1 grade 3 carcinoma of the bladder. J Urol 1992;148: 1420-1426.
37. Yin H, He Q, Li T, Leong AS: Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. Appl Immunohistochem Mol Morphol 2006;14:260-265.
38. Harnden P, Eardley I, Joyce AD, Southgate J: Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 1996; 78:870-875.